Palisade Bio (PALI) Non Operating Income (2010 - 2026)
Palisade Bio (PALI) reported Non Operating Income of $1.1 million for Q1 2026, up 1317.28% year-over-year from $81000.0 in Q1 2025, and up 6.89% on a QoQ basis from $1.1 million in Q4 2025.
Palisade Bio (PALI) has 17 years of Non Operating Income data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Non Operating Income rose 1317.28% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 542.86% YoY) and the FY2025 annual result came in at $1.3 million, up 202.85% from the prior year.
- Non Operating Income grew to $1.1 million in Q1 2026 per PALI's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $1.2 million in Q2 2022 and bottomed at -$317000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $146000.0 (2024), against an average of $298882.4.
- Peak annual rise in Non Operating Income reached 7575.0% in 2022, while the deepest fall reached 97.49% in 2022.
- Tracing PALI's Non Operating Income over 5 years: stood at $128000.0 in 2022, then jumped by 42.97% to $183000.0 in 2023, then slumped by 79.23% to $38000.0 in 2024, then jumped by 2726.32% to $1.1 million in 2025, then climbed by 6.89% to $1.1 million in 2026.
- Per Business Quant, the three latest PALI Non Operating Income figures stand at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $59000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 1.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | 112,000.00 |
| Jun 30, 2024 | 133,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Dec 31, 2023 | 183,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Jun 30, 2023 | 216,000.00 |
| Mar 31, 2023 | 189,000.00 |
| Dec 31, 2022 | 128,000.00 |
| Sep 30, 2022 | 422,000.00 |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | -317,000.00 |
| Dec 31, 2021 | 5.10 Mn |
| Sep 30, 2021 | 11.10 Mn |
| Jun 30, 2021 | 16,000.00 |
| Dec 31, 2020 | -1.04 Mn |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | -10,000.00 |
| Mar 31, 2020 | -5.58 Mn |
| Dec 31, 2019 | 94,969.00 |
| Sep 30, 2019 | 361,041.00 |
| Jun 30, 2019 | 34,989.00 |
| Mar 31, 2019 | -657,427.00 |
| Dec 31, 2018 | 3.34 Mn |
| Sep 30, 2018 | 252,391.00 |
| Jun 30, 2018 | 1.40 Mn |
| Mar 31, 2018 | 202,027.00 |
| Dec 31, 2017 | -1.05 Mn |
| Sep 30, 2017 | 2.45 Mn |
| Jun 30, 2017 | -430,961.00 |
| Mar 31, 2017 | -3.34 Mn |
| Dec 31, 2016 | 255,921.00 |
| Sep 30, 2016 | -303,278.00 |
| Jun 30, 2016 | -18,240.00 |
| Mar 31, 2016 | -372,171.00 |
| Dec 31, 2015 | -413,845.00 |
| Sep 30, 2015 | -440,048.00 |
| Jun 30, 2015 | -453,315.00 |
| Mar 31, 2015 | -440,165.00 |
| Dec 31, 2014 | -5.44 Mn |
| Jun 30, 2014 | -3.24 Mn |
| Dec 31, 2013 | -540,615.00 |
| Sep 30, 2013 | -3.05 Mn |
| Jun 30, 2013 | -3.02 Mn |
| Mar 31, 2013 | -698,307.00 |
| Dec 31, 2012 | 11,862.00 |
| Sep 30, 2012 | 5,768.00 |
| Jun 30, 2012 | 6,874.00 |
| Mar 31, 2012 | 10,435.00 |
| Dec 31, 2011 | 5,637.00 |
| Sep 30, 2011 | 11,463.00 |
| Jun 30, 2011 | 20,143.00 |
| Mar 31, 2011 | 434,701.00 |
| Dec 31, 2010 | 710,524.00 |
| Sep 30, 2010 | -6,594.00 |
| Jun 30, 2010 | -756,249.00 |